SCHEMBL17845289

SCHEMBL17845289

CN(C(=O)O)c1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
KMT2A Q03164 3/20 0.38
GAA P10253 2/20 0.38
MEN1 O00255 1/20 0.38
HSD11B1 P28845 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
FLT1 P17948 2/20 0.36
FLT4 P35916 2/20 0.36
KDR P35968 2/20 0.36
MAPT P10636 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3067655 0.85 HSD11B1 (0.50) ALDH1A1HSD17B10TDP1KDM4EHPGD
SCHEMBL11578256 0.82 ENPP2 (0.48) KMT2AMEN1
SCHEMBL11576437 0.79 PSIP1 (0.50) TDP1GAAHSD11B1KEAP1NFE2L2
SCHEMBL22492234 0.79 ALDH1A1 (0.44) ALDH1A1HSD17B10TDP1KMT2AGAA
SCHEMBL295564 0.77 ALDH1A1 (0.61) ALDH1A1HSD17B10TDP1KDM4EHPGD
SCHEMBL22578640 0.77 ALDH1A1 (0.41) ALDH1A1HSD17B10TDP1KDM4EHPGD
SCHEMBL17863663 0.76 LMNA (0.54) ALDH1A1HPGDKMT2AGAAPOLB
SCHEMBL692996 0.75 ALDH1A1 (0.48) ALDH1A1HSD17B10TDP1KDM4EHPGD
SCHEMBL11788282 0.74 HDAC1 (0.44) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL7834724 0.74 ALDH1A1 (0.58) ALDH1A1HSD17B10TDP1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 US disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 EP disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 ALDH1A1 1411/4885HSD17B10 2344/4885TDP1 233/4885
US-20180194738-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ALDH1A1 1483/4885HSD17B10 2507/4885TDP1 223/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 ALDH1A1 1483/4885HSD17B10 2507/4885TDP1 223/4885
US-20200165208-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ALDH1A1 1483/4885HSD17B10 2507/4885TDP1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.